|
1
|
Pizzo PA PD: Principles and Practice of
Pediatric Oncology. Sixth edition. Wolters Kluwer Health/Lippincott
Williams and Wilkins; Philadelphia: 2010
|
|
2
|
Smith MA, Altekruse SF, Adamson PC, Reaman
GH and Seibel NL: Declining childhood and adolescent cancer
mortality. Cancer. 120:2497–2506. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
American Cancer Society, . Key Statistics
About Neuroblastoma. https://www.cancer.org/cancer/neuroblastoma/about/key-statistics.htmlDecember
17–2021
|
|
4
|
Siegel RL, Miller KD, Fuchs HE and Jemal
A: Cancer Statistics, 2021. CA Cancer J Clin. 71:7–33. 2021.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Park JR, Kreissman SG, London WB, Naranjo
A, Cohn SL, Hogarty MD, Tenney SC, Haas-Kogan D, Shaw PJ, Kraveka
JM, et al: Effect of tandem autologous stem cell transplant vs
single transplant on event-free survival in patients with high-risk
neuroblastoma: A randomized clinical trial. JAMA. 322:746–755.
2019. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Matthay KK, Maris JM, Schleiermacher G,
Nakagawara A, Mackall CL, Diller L and Weiss WA: Neuroblastoma. Nat
Rev Dis Primers. 2:160782016. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Wieczorek M, Bechstedt S, Chaaban S and
Brouhard GJ: Microtubule-associated proteins control the kinetics
of microtubule nucleation. Nat Cell Biol. 17:907–916. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Neumayer G, Belzil C, Gruss OJ and Nguyen
MD: TPX2: Of spindle assembly, DNA damage response, and cancer.
Cell Mol Life Sci. 71:3027–3047. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Heidebrecht HJ, Buck F, Steinmann J,
Sprenger R, Wacker HH and Parwaresch R: p100: A novel
proliferation-associated nuclear protein specifically restricted to
cell cycle phases S, G2, and M. Blood. 90:226–233. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Garrido G and Vernos I: Non-centrosomal
TPX2-dependent regulation of the Aurora a kinase: Functional
implications for healthy and pathological cell division. Front
Oncol. 6:882016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Moss DK, Wilde A and Lane JD: Dynamic
release of nuclear RanGTP triggers TPX2-dependent microtubule
assembly during the apoptotic execution phase. J Cell Sci 122(Pt
5). 644–655. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yan L, Li Q, Yang J and Qiao B:
TPX2-p53-GLIPR1 regulatory circuitry in cell proliferation,
invasion, and tumor growth of bladder cancer. J Cell Biochem.
119:1791–1803. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Tomii C, Inokuchi M, Takagi Y, Ishikawa T,
Otsuki S, Uetake H, Kojima K and Kawano T: TPX2 expression is
associated with poor survival in gastric cancer. World J Surg
Oncol. 15:142017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhu H, Liu J, Feng J, Zhang Q, Bian T, Li
X, Sun H, Zhang J and Liu Y: Overexpression of TPX2 predicts poor
clinical outcome and is associated with immune infiltration in
hepatic cell cancer. Medicine (Baltimore). 99:e235542020.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sillars-Hardebol AH, Carvalho B, Tijssen
M, Beliën JA, de Wit M, Delis-van Diemen PM, Pontén F, van de Wiel
MA, Fijneman RJ and Meijer GA: TPX2 and AURKA promote 20q
amplicon-driven colorectal adenoma to carcinoma progression. Gut.
61:1568–1575. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Shah KN, Bhatt R, Rotow J, Rohrberg J,
Olivas V, Wang VE, Hemmati G, Martins MM, Maynard A, Kuhn J, et al:
Aurora kinase A drives the evolution of resistance to
third-generation EGFR inhibitors in lung cancer. Nat Med.
25:111–118. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Ognibene M, Podestà M, Garaventa A and
Pezzolo A: Role of GOLPH3 and TPX2 in neuroblastoma DNA damage
response and cell resistance to chemotherapy. Int J Mol Sci.
20:47642019. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Irwin MS, Naranjo A, Zhang FF, Cohn SL,
London WB, Gastier-Foster JM, Ramirez NC, Pfau R, Reshmi S, Wagner
E, et al: Revised neuroblastoma risk classification system: A
report from the children's oncology group. J Clin Oncol.
39:3229–3241. 2021. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Bosse KR and Maris JM: Advances in the
translational genomics of neuroblastoma: From improving risk
stratification and revealing novel biology to identifying
actionable genomic alterations. Cancer. 122:20–33. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Cohn SL, Pearson AD, London WB, Monclair
T, Ambros PF, Brodeur GM, Faldum A, Hero B, Iehara T, Machin D, et
al: The International neuroblastoma risk group (INRG)
classification system: An INRG Task Force report. J Clin Oncol.
27:289–297. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Nakagawara A, Li Y, Izumi H, Muramori K,
Inada H and Nishi M: Neuroblastoma. Jpn J Clin Oncol. 48:214–241.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Matsushita K, Uchida K, Saigusa S, Ide S,
Hashimoto K, Koike Y, Otake K, Inoue M, Tanaka K and Kusunoki M:
Glycolysis inhibitors as a potential therapeutic option to treat
aggressive neuroblastoma expressing GLUT1. J Pediatr Surg.
47:1323–1330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Mossé YP, Fox E, Teachey DT, Reid JM,
Safgren SL, Carol H, Lock RB, Houghton PJ, Smith MA, Hall D, et al:
A phase II study of alisertib in children with recurrent/refractory
solid tumors or leukemia: Children's oncology group phase I and
pilot consortium (ADVL0921). Clin Cancer Res. 25:3229–3238. 2019.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Tonini GP, Boni L, Pession A, Rogers D,
Iolascon A, Basso G, Cordero di Montezemolo L, Casale F, Pession A,
Perri P, et al: MYCN oncogene amplification in neuroblastoma is
associated with worse prognosis, except in stage 4s: The Italian
experience with 295 children. J Clin Oncol. 15:85–93. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Bayliss R, Sardon T, Vernos I and Conti E:
Structural basis of Aurora-A activation by TPX2 at the mitotic
spindle. Mol Cell. 12:851–862. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Asteriti IA, Rensen WM, Lindon C, Lavia P
and Guarguaglini G: The Aurora-A/TPX2 complex: A novel oncogenic
holoenzyme? Biochim Biophys Acta. 1806:230–239. 2010.PubMed/NCBI
|
|
28
|
Lake EW, Muretta JM, Thompson AR,
Rasmussen DM, Majumdar A, Faber EB, Ruff EF, Thomas DD and Levinson
NM: Quantitative conformational profiling of kinase inhibitors
reveals origins of selectivity for Aurora kinase activation states.
Proc Natl Acad Sci USA. 115:e11894–e11903. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Neumayer G, Helfricht A, Shim SY, Le HT,
Lundin C, Belzil C, Chansard M, Yu Y, Lees-Miller SP, Gruss OJ, et
al: Targeting protein for xenopus kinesin-like protein 2 (TPX2)
regulates γ-histone 2AX (γ-H2AX) levels upon ionizing radiation. J
Biol Chem. 287:42206–42222. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pérez de Castro I and Malumbres M: Mitotic
stress and chromosomal instability in cancer: The case for TPX2.
Genes Cancer. 3:721–730. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Do TV, Hirst J, Hyter S, Roby KF and
Godwin AK: Aurora A kinase regulates non-homologous end-joining and
poly(ADP-ribose) polymerase function in ovarian carcinoma cells.
Oncotarget. 8:50376–50392. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Liu Y, Parry JA, Chin A, Duensing S and
Duensing A: Soluble histone H2AX is induced by DNA replication
stress and sensitizes cells to undergo apoptosis. Mol Cancer.
7:612008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
van Gijn SE, Wierenga E, van den Tempel N,
Kok YP, Heijink AM, Spierings DCJ, Foijer F, van Vugt MATM and
Fehrmann RSN: TPX2/Aurora kinase A signaling as a potential
therapeutic target in genomically unstable cancer cells. Oncogene.
38:852–867. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Niu H, Manfredi M and Ecsedy JA:
Scientific rationale supporting the clinical development strategy
for the investigational Aurora a kinase inhibitor alisertib in
cancer. Front Oncol. 5:1892015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Ma Y, Lin D, Sun W, Xiao T, Yuan J, Han N,
Guo S, Feng X, Su K, Mao Y, et al: Expression of targeting protein
for xklp2 associated with both malignant transformation of
respiratory epithelium and progression of squamous cell lung
cancer. Clin Cancer Res. 12:1121–1127. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Liang B, Jia C, Huang Y, He H, Li J, Liao
H, Liu X, Liu X, Bai X and Yang D: TPX2 level correlates with
hepatocellular carcinoma cell proliferation, apoptosis, and EMT.
Dig Dis Sci. 60:2360–2372. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Warner SL, Stephens BJ, Nwokenkwo S,
Hostetter G, Sugeng A, Hidalgo M, Trent JM, Han H and Von Hoff DD:
Validation of TPX2 as a potential therapeutic target in pancreatic
cancer cells. Clin Cancer Res. 15:6519–6528. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Shigeishi H, Ohta K, Hiraoka M, Fujimoto
S, Minami M, Higashikawa K and Kamata N: Expression of TPX2 in
salivary gland carcinomas. Oncol Rep. 21:341–344. 2009.PubMed/NCBI
|
|
39
|
Chang H, Wang J, Tian Y, Xu J, Gou X and
Cheng J: The TPX2 gene is a promising diagnostic and therapeutic
target for cervical cancer. Oncol Rep. 27:1353–1359.
2012.PubMed/NCBI
|
|
40
|
Ooi WF, Re A, Sidarovich V, Canella V,
Arseni N, Adami V, Guarguaglini G, Giubettini M, Scaruffi P,
Stigliani S, et al: Segmental chromosome aberrations converge on
overexpression of mitotic spindle regulatory genes in high-risk
neuroblastoma. Genes Chromosomes Cancer. 51:545–556. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Takahashi Y, Sheridan P, Niida A, Sawada
G, Uchi R, Mizuno H, Kurashige J, Sugimachi K, Sasaki S, Shimada Y,
et al: The AURKA/TPX2 axis drives colon tumorigenesis cooperatively
with MYC. Ann Oncol. 26:935–942. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Richards MW, Burgess SG, Poon E,
Carstensen A, Eilers M, Chesler L and Bayliss R: Structural basis
of N-Myc binding by Aurora-A and its destabilization by kinase
inhibitors. Proc Natl Acad Sci USA. 113:13726–13731. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Dauch D, Rudalska R, Cossa G, Nault JC,
Kang TW, Wuestefeld T, Hohmeyer A, Imbeaud S, Yevsa T, Hoenicke L,
et al: A MYC-Aurora kinase A protein complex represents an
actionable drug target in p53-altered liver cancer. Nat Med.
22:744–753. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Wei P, Zhang N, Xu Y, Li X, Shi D, Wang Y,
Li D and Cai S: TPX2 is a novel prognostic marker for the growth
and metastasis of colon cancer. J Transl Med. 11:3132013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Huang Y, Guo W and Kan H: TPX2 is a
prognostic marker and contributes to growth and metastasis of human
hepatocellular carcinoma. Int J Mol Sci. 15:18148–18161. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Chu TLH, Connell M, Zhou L, He Z, Won J,
Chen H, Rahavi SMR, Mohan P, Nemirovsky O, Fotovati A, et al: Cell
cycle-dependent tumor engraftment and migration are enabled by
Aurora-A. Mol Cancer Res. 16:16–31. 2018. View Article : Google Scholar : PubMed/NCBI
|
